Biotech stocks Kairos, OS Therapies, and AEON experience significant retail interest and stock price spikes.

From StockTwits: 2025-01-21 10:08:13

Investor interest in biotech stocks has surged due to advancements in cancer treatments and FDA breakthroughs. Kairos Pharma saw an 83% increase in retail chatter after breaking key resistance levels and securing investments. OS Therapies reported positive clinical trial data for its OST-HER2 candidate, leading to a 39% jump in shares. AEON Biopharma, developing a botulinum toxin complex, saw a 19% increase in stock price. Despite recent gains, Kairos has lost 21% of its value since its NYSE debut in September. For more information, contact newsroom[at]stocktwits[dot]com.



Read more at StockTwits: Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here’s Why